Vivaldi Biosciences

About:

Vivaldi Biosciences develops influenza vaccines and therapeutics for seasonal and pandemic influenza.

Website: http://www.vivaldibiosciences.com

Top Investors: Bay City Capital, NGN Capital

Description:

Vivaldi Biosciences Inc. develops influenza vaccines and therapeutics for seasonal and pandemic influenza through a small molecule program targeting the NS1 protein of influenza. The company was founded in 2006 and is based in San Francisco, California.

Total Funding Amount:

$27M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)vivaldibiosciences.com

Founders:

Adolfo García-Sastre, Elliott Kieff, Peter Palese

Number of Employees:

11-50

Last Funding Date:

2010-07-08

IPO Status:

Private

Industries: